Arcutis Biotherapeutics Inc (ARQT)
9.43
+0.17
(+1.84%)
USD |
NASDAQ |
Nov 18, 16:00
9.45
+0.02
(+0.21%)
After-Hours: 20:00
Arcutis Biotherapeutics Debt to Equity Ratio: 1.306 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.306 |
| June 30, 2024 | 1.093 |
| March 31, 2024 | 0.9016 |
| December 31, 2023 | 2.276 |
| September 30, 2023 | 4.298 |
| Date | Value |
|---|---|
| June 30, 2023 | 2.481 |
| March 31, 2023 | 1.422 |
| December 31, 2022 | 0.9436 |
| September 30, 2022 | 0.7266 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.7266
Minimum
Sep 2022
4.298
Maximum
Sep 2023
1.716
Average
1.306
Median
Sep 2024
Debt to Equity Ratio Benchmarks
| Mirum Pharmaceuticals Inc | 1.326 |
| Biogen Inc | 0.3847 |
| Vertex Pharmaceuticals Inc | 0.00 |
| NovaBay Pharmaceuticals Inc | 0.0476 |
| Palatin Technologies Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 437.35M |
| Total Liabilities (Quarterly) | 280.71M |
| Shareholders Equity (Quarterly) | 156.64M |
| Current Ratio | 2.457 |
| Net Debt Paydown Yield | -0.09% |